At Balancial we use quality systems, regulatory procedures, and a data-based mindset from the pharmaceutical industry

Balancial is a Nordic medicinal cannabis company dedicated to the highest quality assurance procedures. Our rigorous testing and dedication to regulatory compliance ensure safe, authorised and trusted medicinal cannabis products.

Bo Tandrup, Pharmacist.

LEARN

Guidelines for doctors

The Danish Medicines Agency has compiled comphrehensive guidelines for physicians' treatment of patients with medical cannabis.

Read more

TEST/Quality

We are deeply focused on testing and quality assurance and are fully licensed

Licensed by the Danish Medicines Agency

LEARN

Guidelines for doctors

The Danish Medicines Agency has compiled comphrehensive guidelines for physicians' treatment of patients with medical cannabis.

Read more

TEST/Quality

We are deeply focused on testing and quality assurance and are fully licensed

Message from the CEO

Bo Tandrup

CEO

Medicinal cannabis is a controversial subject. We acknowledge that Doctors are sceptical towards non-authorised medicines with inadequate knowledge of effects and side-effects, but a few important facts should be emphasized.

Firstly, although not exhaustive, we do have some clinical data to support the use of medicinal cannabis. The Danish Medicines Agency has prepared guidelines for doctors based on extensive literature searches, assessments of the review of scientific evidence from the National Academy of Sciences (USA, 2017), evaluation of cannabis schemes in other countries and evaluation of the data leading to previous licensing of cannabis-containing medicines in Europe and the USA.

Secondly, medicinal cannabis is not a substitute for authorised medicines. It is to be tried only if the patient has not benefitted from the treatment with relevant authorised medicine.

Finally, the intention with the Danish pilot programme is to provide a better basis to assess the use of medicinal cannabis. Therefore, quality assured medicinal cannabis products should be made available as long as such products are admitted or approved by the Danish Medicines Agency.

At Balancial we are pharmaceutical industry professionals. We confer with doctors from various clinical fields, select products based on their recommendations and assure that they conform with any and all regulatory requirements before we make them available on the Danish market.

Guidelines for doctors

Balancial’s products should be considered only for the following indications that are supported by some evidence:

  • Painful spasms caused by multiple sclerosis
  • Painful spasms caused by spinal cord damage
  • Nausea after chemotherapy
  • Neuropathic pain, i.e. pain due to a disease of the brain, spinal cord or nerves

Products

Learn about
our products

Product coming soon
Product coming soon
Read more

Your patients will ask for your guidance. Stay openminded and informed.

“While acknowledging the necessity of more research, it is a fact that an increasing number of patients report the need for medicinal cannabis because they experience that it helps them personally. But until each clinical specialty has prepared their own treatment recommendations, medicinal cannabis can only be regarded as an important supplement to existing registered pharmaceutical products.”

Dr. Peter Leutscher
Professor
Chief Physician

Our team of industry experts who work passionately to unfold the potential of medicinal cannabis

Bo Tandrup

CEO
Bo has a background in product development and project management in the pharma industry. He is behind several successful start-ups in the pharmaceutical industry and has been hired as an advisor to, among others, Goldman Sachs and McKinsey in processes related to acquisitions in the pharmaceutical industry. Bo holds a Master’s degree in Pharmaceutical Sciences from the Royal Danish School of Pharmacy.

Birgit Bundgaard

Competent Person / Quality Assurance
Birgit Bundgaard joined Balancial in July 2021 as «Competent Person» and is responsible for Balancial's QMS system. Birgit has extensive experience in quality systems and prior to joining Balancial she worked as Qualified Person for Lundbeck. Birgit holds a Master’s degree in Pharmaceutical Sciences from the Royal Danish School of Pharmacy.

Carla Ferrao

GMP Technician
Carla Ferrao first joined Balancial as GMP Technician but quickly advanced and assumed responsibility for Regulatory Affairs. Prior to joining Balancial Carla worked at the National Food Institute at the Technical University of Denmark. Carla holds a Master’s degree in Chemical Engineering from the University of Southern Denmark.

Lars Erik Råen

Chairman, Balancial AS
Background from banking and finance, business development, and as an investor. Has in recent years been involved in development, and financing for several start-ups in Norway and internationally. Co-founder of Balancial and has been a full-time working chairman of the board since 2020. Lars holds a Bachelor of Finance degree from Norwegian School of Business.

Nedim Mavric

Chairman, Balancial Danmark ApS
Nedim is strategy advisor and chairman of the board in Denmark. He has international experience with a background in investment banking and financial markets and is now working as an entrepreneur. Nedim started his career at Nordea Bank and has since been instrumental in setting up several ventures and business lines. Nedim holds a MSc in Business and Financial Economics.

Daniel Petter Lunde

CFO, Balancial AS
Daniel has long and broad experience from the financial sector, where he held different positions within corporate finance. He has since 2017, served as managing partner of the investment and consultancy firm Westpoint Partners (majority shareholder in Balancial). Daniel is a co-founder of Balancial, and took the position as CFO in 2021. He holds a BSc in Economics & Administration, with a major in Business Development.